Tirosint Cost in South Dakota 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does It Cost More Than Generic Levothyroxine?

Tirosint is a branded, alcohol-free liquid gel capsule formulation of levothyroxine sodium manufactured by IBSA Institut Biochimique SA. It contains only four excipients: levothyroxine sodium, gelatin, glycerin, and water. Standard levothyroxine tablets contain fillers including lactose, acacia, and confectioner's sugar, which can impair absorption in patients with celiac disease, lactose intolerance, or gastric achlorhydria [1].

The clinical case for the gel cap rests on pharmacokinetic data. Vita et al. (Endocrine, 2014) demonstrated that switching 36 hypothyroid patients with impaired levothyroxine absorption from tablet to liquid levothyroxine produced statistically significant TSH normalization (mean TSH fell from 8.3 to 2.8 mIU/L, P<0.001) [2]. That absorption advantage is what justifies its higher price point relative to generic tablets, which retail for $4, $10 per month at major South Dakota chains like Walmart and Walgreens.

The FDA approved Tirosint under NDA 022417 [3]. The prescribing information confirms the gel capsule formulation is bioequivalent to the reference standard and notes that food, calcium, and antacids still reduce levothyroxine absorption and should be separated by at least 4 hours [3].

Thyroid hormone replacement is one of the most commonly prescribed drug classes in the United States. The American Thyroid Association (ATA) 2014 guidelines recommend levothyroxine as the standard of care for hypothyroidism [4]. When absorption is compromised, the ATA guidelines explicitly state that "alternative formulations such as liquid or soft gel capsule preparations may be appropriate" [4].

Tirosint Cash Price in South Dakota in 2026

The manufacturer list price for Tirosint in South Dakota is approximately $230 per month for a 30-day supply. That figure represents the average retail cash price across SD pharmacies in 2026 based on current IBSA wholesale acquisition cost data.

No major South Dakota pharmacy chain offers a generic equivalent to Tirosint's liquid gel cap format. Mylan and Lannett manufacture levothyroxine tablets at far lower costs, but tablet and gel cap formulations are not automatically substitutable because they are rated differently under FDA's Orange Book [3]. A pharmacist cannot swap one for the other without prescriber authorization.

Patients paying cash should compare prices across multiple dispensers. GoodRx and similar discount platforms sometimes list Tirosint at $180, $210 for select South Dakota ZIP codes, though availability varies by pharmacy and coupon expiration. The IBSA savings card (discussed below) generally provides a deeper discount for eligible patients than third-party coupon sites.

The absorption differences documented in peer-reviewed literature matter for cost-effectiveness calculations. If a patient on standard tablets requires dose escalation due to poor absorption, the added lab costs, follow-up visits, and cardiovascular risk from prolonged hypothyroidism may outweigh the price premium of the gel cap [5]. A 2019 analysis in Frontiers in Endocrinology found that malabsorption-driven dose escalation added measurable downstream costs to hypothyroidism management [5].

Does South Dakota Medicaid Cover Tirosint?

South Dakota Medicaid does not cover Tirosint. The SD Medicaid preferred drug list (PDL) covers generic levothyroxine tablets as the preferred agent for hypothyroidism. Tirosint is a non-preferred brand with no current prior authorization pathway that guarantees approval in the South Dakota Medicaid program.

Medicaid coverage of branded thyroid medications varies substantially by state. Several states allow prior authorization for Tirosint when a prescriber documents a clinical reason such as celiac disease, documented malabsorption, or persistent above-target TSH on tablets despite confirmed adherence. South Dakota has not published a blanket prior authorization criteria document permitting Tirosint at this time.

Patients enrolled in South Dakota's Medicaid expansion population (adults up to 138% of the federal poverty level, per the ACA) who require Tirosint for clinical reasons have two practical pathways: (1) appeal through the SD Department of Social Services requesting medical necessity review, or (2) transition to compounded levothyroxine gel caps from a licensed 503A pharmacy, which may carry a lower or zero cost depending on the prescriber's clinical arrangement.

The Centers for Medicare and Medicaid Services (CMS) provides guidance on state PDL exceptions processes [6]. Patients or prescribers seeking a Medicaid exception should submit documentation including TSH trend data on tablets, evidence of malabsorption diagnosis (endoscopy, anti-tTG antibody titers, or achlorhydria pH testing), and a letter of medical necessity.

Is Compounded Levothyroxine Legal in South Dakota?

Yes. Compounded levothyroxine liquid or gel capsules prepared by a licensed 503A compounding pharmacy are legal in South Dakota. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits state-licensed pharmacies to compound drugs for identified individual patients based on valid prescriptions [7].

South Dakota does not maintain a state-specific prohibition on compounded thyroid preparations. The South Dakota Board of Pharmacy licenses and inspects 503A pharmacies operating within the state, and out-of-state 503A pharmacies may ship compounded levothyroxine to South Dakota patients provided they hold appropriate non-resident pharmacy licensure.

Compounded levothyroxine gel capsules are not FDA-approved drug products. The FDA has noted that compounded drugs lack the clinical testing requirements applied to approved products [7]. The ATA and the American Association of Clinical Endocrinologists (AACE) advise prescribers to use compounded thyroid preparations only when commercially available products do not meet a patient's clinical needs [8]. Both organizations caution that potency and stability in compounded preparations may vary compared to FDA-approved formulations [8].

Cost is the primary driver of interest in compounded alternatives. A licensed 503A pharmacy may supply compounded levothyroxine gel capsules at costs ranging from $0 (through specific clinical programs) to $40, $80 per month, compared to $230 per month for brand Tirosint. Patients must weigh the cost savings against the absence of FDA manufacturing oversight.

The FDA's guidance on 503A compounding pharmacies is publicly available and outlines the conditions under which compounding is permissible [7]. Prescribers in South Dakota who write for compounded levothyroxine should document the clinical rationale in the patient's chart.

Which Insurance Plans Cover Tirosint in South Dakota?

Commercial insurance coverage for Tirosint in South Dakota depends on the insurer's formulary tier structure. Most major plans, including Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Wellmark, place Tirosint on a Tier 3 or Tier 4 (non-preferred brand) level. Out-of-pocket costs at those tiers typically run $60, $120 per 30-day fill before the deductible is met and $30, $80 after.

Medicare Part D plans operating in South Dakota cover levothyroxine tablets on low-cost tiers but generally do not include Tirosint on standard formularies. Patients may request a formulary exception from their Part D plan by submitting a prescriber attestation that Tirosint is medically necessary and that generic tablets are clinically inadequate. CMS regulations at 42 CFR §423.578 require Part D plans to have a formulary exception process [6].

Employer-sponsored health plans in South Dakota follow their pharmacy benefits manager (PBM) formularies. Express Scripts, OptumRx, and CVS Caremark each manage formularies used by SD employers. Tirosint's coverage status changes annually with each PBM formulary update; patients should verify their plan's current tier assignment during open enrollment.

Prior authorization (PA) for Tirosint under commercial plans commonly requires documentation of at least one of the following: a diagnosis of celiac disease confirmed by duodenal biopsy or positive anti-tissue transglutaminase (anti-tTG) IgA with TSH above goal on tablets; a diagnosis of achlorhydria or atrophic gastritis; or at least two TSH values above 5.0 mIU/L on adequate tablet doses with confirmed adherence [9].

How the IBSA Savings Card Works in South Dakota

IBSA offers a branded savings card for Tirosint through its patient support program. Commercially insured patients who are not enrolled in any federal or state government insurance program (including Medicaid, Medicare, TRICARE, or VA benefits) may be eligible to pay as little as $0 per month copay.

The card is available directly through the Tirosint manufacturer website or via the prescribing provider. Eligibility criteria include: valid commercial insurance that covers Tirosint at any tier, residence in the United States (South Dakota qualifies), and not being a beneficiary of a federal health program [10].

The savings card does not function as insurance. It is a manufacturer copay offset program. The card covers the gap between the plan's copay and the patient's out-of-pocket maximum for Tirosint fills at participating pharmacies. Most major South Dakota retail pharmacies (Walgreens, CVS, Hy-Vee Pharmacy, Avera pharmacies) participate in copay card processing.

Patients whose plans require a PA before covering Tirosint must obtain the PA approval before the savings card becomes usable. The PA and the savings card are separate processes.

The HealthRX clinical team uses the following three-step cost-access decision framework for South Dakota Tirosint patients:

Step 1. Confirm clinical indication. TSH above goal on tablets despite documented adherence, or a diagnosis (celiac, achlorhydria, bariatric surgery) explaining malabsorption. Order anti-tTG IgA serology or gastric pH testing if not already documented [9].

Step 2. Run insurance verification before writing the prescription. Determine the patient's formulary tier, PA requirements, and copay. If the plan requires PA, submit supporting lab data and diagnosis codes simultaneously with the prescription.

Step 3. Layer cost-reduction options. If the patient has commercial insurance: apply the IBSA savings card. If South Dakota Medicaid: initiate a medical necessity appeal and simultaneously evaluate licensed 503A compounding as a bridge. If Medicare Part D: file a formulary exception with a prescriber letter. If uninsured: compare compounded levothyroxine gel caps at a licensed 503A pharmacy against GoodRx pricing for brand Tirosint.

Can You Get a Tirosint Prescription via Telehealth in South Dakota?

Yes. Telehealth prescribing of Tirosint is legal in South Dakota. South Dakota participates in the Interstate Medical Licensure Compact (IMLC), and the state's telehealth statute (SDCL Title 36) permits synchronous audio-video encounters as the basis for a valid prescriber-patient relationship [11].

A licensed South Dakota physician, advanced practice registered nurse (APRN), or physician assistant (PA) may evaluate a patient for hypothyroidism via a telehealth visit and write a Tirosint prescription. The prescription must meet all standard state requirements: patient name, date, drug name and strength, quantity, directions, and prescriber DEA number or NPI.

Levothyroxine is not a controlled substance under the DEA Schedules, so no in-person visit is required under federal law specifically for this drug. South Dakota does not impose a separate state-level controlled substance prescribing restriction that would apply to levothyroxine [11].

Remote prescribing platforms operating in South Dakota must hold a valid SD telehealth license or IMLC membership. Patients using HealthRX or similar platforms should confirm the prescribing clinician is licensed in South Dakota before the visit.

TSH monitoring after initiating or adjusting levothyroxine dose should occur at 6 to 8 weeks post-change, per ATA guidelines [4]. Telehealth-ordered labs can be drawn at LabCorp, Quest Diagnostics, or Sanford Health laboratories throughout South Dakota.

Absorption, Clinical Outcomes, and the Case for Gel Cap Formulation

Levothyroxine absorption from standard tablets averages 60 to 80% under ideal fasting conditions, according to data reviewed in the FDA's reference standard monograph [3]. Absorption drops further when patients take tablets with coffee, calcium supplements, proton pump inhibitors (PPIs), or iron, all of which are common in hypothyroid populations.

Cappelli et al. (2016) demonstrated in a prospective crossover study (N=56) that switching from tablet to liquid levothyroxine in patients on PPIs normalized TSH in 34 of 56 subjects (61%) without any dose change [12]. That finding matters for South Dakota patients: PPI use in the US adult population is estimated at 15% by the NIH [13], and many hypothyroid patients are on PPIs concurrently.

A 2017 study by Fallahi et al. published in the Journal of Thyroid Research found that patients with Hashimoto's thyroiditis who switched from tablet to liquid levothyroxine showed TSH normalization rates significantly above those on equivalent tablet doses, with P<0.05 for the primary endpoint [14]. Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions including the United States, affecting an estimated 14 million Americans [15].

The pharmacokinetic rationale is straightforward. Gel cap levothyroxine dissolves in gastric fluid independent of tablet disintegration, bypassing the rate-limiting step where gastric pH and bile salts affect tablet breakdown [2]. This mechanism explains why Vita et al. found significant TSH improvement in patients with gastric achlorhydria when switched to liquid formulation [2].

For South Dakota patients with any of the following conditions, a prescriber may consider Tirosint or compounded gel cap levothyroxine as the preferred starting formulation rather than a fallback: celiac disease (prevalence approximately 1% of the US population [16]), atrophic gastritis, H. pylori-associated hypochlorhydria, Roux-en-Y gastric bypass, and chronic PPI use of greater than 6 months.

Monitoring TSH After Starting Tirosint in South Dakota

After switching from levothyroxine tablets to Tirosint, TSH should be rechecked at 6 to 8 weeks. Because Tirosint's superior absorption may effectively increase the bioavailable dose, some patients require a dose reduction after the switch. The ATA recommends checking TSH 6 to 8 weeks after any dose change, and annually once stable [4].

The TSH reference range most US laboratories use is 0.5, 4.5 mIU/L. Some endocrinologists target a narrower range of 1.0, 2.5 mIU/L for younger patients or those with persistent symptoms at the high end of normal [4]. Free T4 is a useful adjunct when TSH is suppressed or when central hypothyroidism is suspected [4].

South Dakota patients can access TSH lab draws at Sanford Health, Avera Health, Monument Health, and independent Lab Corp/Quest draw sites across Sioux Falls, Rapid City, Aberdeen, Watertown, and Brookings. Most telehealth platforms that prescribe Tirosint will order labs electronically and receive results in the patient's chart without requiring an in-person visit.

Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast, or 3 to 4 hours after the last meal at night, per FDA labeling [3]. Patients switching to Tirosint gel caps should continue this timing protocol.